"We are excited to launch DRAGEN v4.3, with significant enhancements and additions to our analysis tools, empowering researchers and geneticists to maximize the value of the genome," said Rami Mehio, head of Software & Informatics at Illumina. "DRAGEN v4.3 includes our next-generation and most accurate multigenome mapping technology, built-in mosaic calling, advancements in machine learning, and the ability to genotype difficult genes to unlock deeper insights into the human genome with greater power, accur ...

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Illumina Inc (ILMN) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering.This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. ...

INDIA - 2023/12/16: In this photo illustration, the Illumina logo is seen displayed on a mobile ... [+] phone screen. (Photo Illustration by Idrees Abbas/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIllumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company’s decision to spin off its blood testing company – Grail. Illumina acquired Grail in ...

文章核心观点 - 美国众议员Thomas Kean Jr.在4月进行了股票交易,买入了Illumina公司股票,卖出了耐克公司股票 [1] - Illumina公司是基因测序领域的领导者,该行业预计未来几年将保持高速增长 [6] - 耐克公司股价在今年前几个月表现较弱,可能是Kean卖出的原因 [5] Illumina公司 - Illumina公司CEO在2月份曾大量买入公司股票,这可能是Kean买入的原因 [3] - Illumina公司在2024年第一季度财报中表现强劲 [4] - Illumina公司所在的基因测序行业预计未来几年将以21.7%的复合年增长率快速增长 [6] 耐克公司 - 耐克公司股价在今年前几个月下跌12%,表现较弱,可能是Kean卖出的原因 [5] - 耐克公司目前股价相对于过去5年的平均水平有一定折价 [7]

"We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output—all at lower cost per kit," said Jason Johnson, head of Global Product Management at Illumina. "XLEAP-SBS chemistry on NextSeq 1000/2000 will enable labs to perform bigger NGS projects without raising the budget, and facilitate greater adoption of multiomic approaches."In March, the company launched its P4 flow cell (highest output of 540 Gb) with XLEAP-SBS chemistry fo ...

"When-issued" trading expected to begin on or about June 12, 2024Record date for distribution of GRAIL shares will be June 13, 2024Distribution date for GRAIL shares anticipated to be June 24, 2024SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on June 24, 2024, and has applied to list on Nasdaq as "GRAL.""Today's announcement marks a milestone for Illumina and ...

Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10.    Illumina, Inc., today announced the appointment of Everett Cunningham as Chief Commercial Officer, eff ...

Illumina, Inc. (NASDAQ:ILMN) Bernstein Strategic Decisions Conference May 29, 2024 9:00 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Salli Schwartz - Vice President, Investor Relations Conference Call Participants Eve Burstein - Bernstein Research Eve Burstein Thanks so much for joining us. My name is Eve Burstein. I cover US life science, tools and diagnostics here at Bernstein. And I'm delighted to be joined by our Illumina friends. So Ankur Dhingra, CFO, Salli Schwartz, Head of IR. ...

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRDSAN DIEGO, May 29, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of its latest research being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4 in Chicago. Highlights ...

SAN DIEGO, May 28, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility (CSR) Report. The report highlights the company's ongoing commitments and progress made in 2023 toward advancing human health by serving as a champion for patients, communities, employees, and the planet.Illumina released its 2023 CSR Report today, highlighting the company’s ongoing commitments and progress made ...